SIGN
The Scottish Intercollegiate Guidelines Network (SIGN) aims to improve the quality of health care for patients in Scotland by reducing variation in practice and outcome, through the development and dissemination of national clinical guidelines containing recommendations for effective practice based on current evidence.
Contact info
- Website:
- www.sign.ac.uk
SIGN guidelineSIGN delirium guideline
This guideline summary provides recommendations based on current evidence for best practice in the detection, assessment, treatment, and follow up of adults with delirium, as well as reducing the risk of delirium. The guideline excludes delirium secondary solely to alcohol and illicit substance use. It also excludes delirium in children.
- SIGN guideline
SIGN chronic pain guideline
This easy-to-read summary of SIGN's guideline describes pharmacological, psychological, and alternative approaches to the management of chronic pain.
- SIGN guideline
SIGN cardiac arrhythmias guideline
Read the latest recommendations on the management of atrial fibrillation and ventricular arrhythmias in acute coronary syndrome, coronary heart disease, and left-ventricular dysfunction as well as arrhythmias associated with cardiac arrest and coronary artery bypass graft.
- SIGN guideline
SIGN FASD guideline
Failure to recognise prenatal alcohol exposure as a possible cause of behavioural difficulties may contribute to adverse outcomes for the child.
- SIGN guideline
SIGN stable angina guideline
This summary includes management algorithms for patients with suspected angina, and patients with a definite diagnosis of stable angina.
- SIGN guideline
SIGN migraine guideline
This Guidelines summary covers the pharmacological options for migraines, medication overuse headache, preventative treatment, and a treatment pathway
- SIGN guideline
SIGN type 2 diabetes guideline
This summary provides key recommendations on lifestyle management, treatment options, diabetic CVD, and CKD. Includes a useful treatment algorithm
- SIGN guideline
SIGN CVD guideline
This summary covers estimation of cardiovascular event risk, lifestyle interventions, and pharmacological therapy.
- SIGN guideline
SIGN cutaneous melanoma guideline
Easy-to-read summary of SIGN’s guideline on the management of cutaneous melanoma in primary care.
- SIGN guideline
SIGN autism guideline
A concise summary of SIGN's guideline on autism, which covers non-pharmacological and pharmacological interventions, and service provision.
- SIGN guideline
SIGN chronic heart failure guideline
This summary covers diagnosis, lifestyle, and pharmacological interventions, and includes a diagnostic algorithm for suspected chronic heart failure.
- SIGN guideline
SIGN epilepsy guideline
An up-to-date guideline summary of the diagnosis and management of epilepsy. Includes status epilepticus, AEDs and approach to some specific patient groups.
- SIGN guideline
SIGN glaucoma guideline
This up-to-date summary of SIGN guidance advises on primary care assessment of suspected glaucoma, criteria for referral, and discharge and monitoring.
- SIGN guideline
SIGN suspected UTI in adults guideline
A brief summary of SIGN's guideline on the management of suspected bacterial UTI in adult men and women, pregnant women, and people with catheters.
- SIGN guideline
SIGN osteoporosis guideline
A brief summary of SIGN's guideline on management of osteoporosis and prevention of fragility fractures, including risk factors and a treatment algorithm.
- SIGN guideline
SIGN eczema guideline
An easy-to-read summary of SIGN's guideline on the management of atopic eczema in primary care. Includes information on dietary interventions and referral.
- SIGN guideline
SIGN schizophrenia guideline
Easy-to-read summary of SIGN's guideline on the management of schizophrenia. Includes pharmacological and psychological intervention, and perinatal issues.
- SIGN guideline
SIGN antithrombotics guideline
A clear SIGN guideline summary exploring antiplatelet and anticoagulant agents and indications for their use, including cardiac and cerebrovascular disease.
